Nanomedicine News

RSS

Published Data Suggests Clinical Benefits from Celator CPX-351 in First Relapse AML Patients

Celator Pharmaceuticals, Inc., a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the publication of Phase 2 data evaluating CPX-351 in adult patients with first-relapse acute myeloid leukemia (AML) in Cancer, a peer-reviewed journal of the American Cancer Society.

13 Jan 2015

Sorrento Commences Dosing in TRIal Establishing Bioequivalence Between Cynviloq™ and Albumin-Bound Paclitaxel

Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that over 80 patients randomized in the ongoing TRIBECA™ (TRIal establishing bioequivalence [BE] between Cynviloq™ and Albumin-bound paclitaxel*) registrational trial have been dosed. Sorrento intends to continue enrolling all qualified patients in the current screening process and anticipates having the "last patient in" by the end of January.

13 Jan 2015

Precision NanoSystems and Arcturus Therapeutics Enter Partnership to Produce RNA Medicines

Precision NanoSystems, a leader in the development and application of microfluidics for the manufacture of nanomedicines; and, Arcturus Therapeutics, a leading small interfering RNA (siRNA) and messenger RNA (mRNA) drug discovery and development company, today announced a partnership for the manufacture of RNA medicines.

12 Jan 2015

Tekmira and OnCore to Merge and Create New Global HBV Company

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, and OnCore Biopharma, Inc., a biopharmaceutical company dedicated to discovering, developing and commercializing an all-oral cure for patients suffering from chronic hepatitis B virus (HBV) infection, announced today that they have agreed to merge to create a new leading global HBV company focused on developing a curative regimen for hepatitis B patients by combining multiple therapeutic approaches.

12 Jan 2015

Sangamo BioSciences In-Licenses Nanoparticle Technology for Systemic mRNA Delivery of ZFNs

Sangamo BioSciences, Inc. announced that the company has in-licensed nanoparticle technology to enable systemic messenger RNA (mRNA) delivery of Sangamo's proprietary zinc finger nucleases (ZFNs). mRNA delivery of ZFNs is being used in the development of the next generation of Sangamo's ZFP Therapeutics®.

9 Jan 2015

Major Research Project Receives Grant to Develop Nanoparticle-Based Cancer Treatment

Traditional cancer treatments like radiotherapy and chemotherapy have significant side effects, as they not only affect the cancer tumours, but also the healthy parts of the body. A major new research project will work to develop a treatment that only affects the tumours locally.

8 Jan 2015

NanoViricides Acquires cGMP-Compliant Manufacturing and R&D Facility from Inno-Haven

NanoViricides, Inc., has completed the purchase of the state of the art cGMP-compliant Manufacturing and R&D facility located in Shelton, Connecticut, from Inno-Haven, LLC.

From NanoViricides, Inc 8 Jan 2015

Blend Secures $21 Million Funding to Create mBDCs Encapsulated in Nanoparticles

Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat cancer, announced today that it has secured $21 million in new funding. The new financing includes additional equity investment from a new investor and all of Blend’s existing venture investors in an expansion of the Series B round, as well as debt financing from an institutional investment firm.

8 Jan 2015

$ProNAi Commences Treatment in Wolverine Phase II Study for Relapsed or Refractory Diffuse Large B-Cell Lymphoma$

ProNAi Commences Treatment in Wolverine Phase II Study for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi® platform, today reported that the first patient with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has enrolled in the "Wolverine" Phase II study and been treated with PNT2258. The patient was treated by Dr. Wael Harb, Founder of the Horizon Oncology Center in Lafayette, Indiana.

8 Jan 2015

BIND Therapeutics Enrolls First Patient Expressing KRAS Mutation in Global BIND-014 Phase 2 Trial in NSCLC Patients

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced its 2015 strategic overview and enrollment of the first patient expressing a KRAS mutation in a global, multicenter two-tiered phase 2 trial with BIND-014 in non-small cell lung cancer (NSCLC) patients with KRAS mutant tumors (mutated Kirsten ras oncogene homolog) or squamous histology.

8 Jan 2015

Nanomedicine News

Published Data Suggests Clinical Benefits from Celator CPX-351 in First Relapse AML Patients

Sorrento Commences Dosing in TRIal Establishing Bioequivalence Between Cynviloq™ and Albumin-Bound Paclitaxel

Precision NanoSystems and Arcturus Therapeutics Enter Partnership to Produce RNA Medicines

Tekmira and OnCore to Merge and Create New Global HBV Company

Sangamo BioSciences In-Licenses Nanoparticle Technology for Systemic mRNA Delivery of ZFNs

Major Research Project Receives Grant to Develop Nanoparticle-Based Cancer Treatment

NanoViricides Acquires cGMP-Compliant Manufacturing and R&D Facility from Inno-Haven

Blend Secures $21 Million Funding to Create mBDCs Encapsulated in Nanoparticles

ProNAi Commences Treatment in Wolverine Phase II Study for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

BIND Therapeutics Enrolls First Patient Expressing KRAS Mutation in Global BIND-014 Phase 2 Trial in NSCLC Patients

Combining Nanofluids and Turbulators for Sustainable Energy

Enhancing Material Properties through Nanotube Encapsulation

Brain-Inspired Nano-Tech Promises New Era for Electronics

Breakthrough in 2D Material Growth Opens Doors to Cleaner Energy and Next-Generation Technology

Sustainable Carbon Nanomaterial Gii Set to Transform Energy Storage in Internet of Things Devices

Electrospinning and the Future of Nanotechnology

How Electrospinning is Shaping the Future of Nanotechnology

Conversations on AFM: Applications of BioAFM in Life Science

Sponsored Content

Characterization of Active Pharmaceutical Ingredients, Injectables, and Proteins

The Future of Wound Care: Why Nanofibers are Key to Accelerated Healing

The Evolution of Lipid Nanoparticles

How Emulsion Electrospinning is Transforming Materials